Hepatitis articles within Nature

Featured

  • Article |

    A retrospective analysis using PCR testing, viral enrichment-based sequencing and agnostic metagenomic sequencing finds an association between adeno-associated virus type 2 and paediatric hepatitis of unknown cause.

    • Venice Servellita
    • , Alicia Sotomayor Gonzalez
    •  & Charles Y. Chiu

  • Letter |

    Phylogenies reconstructed using 12 hepatitis B virus genomes, which were recovered from ancient human genome data, reveal a complex history of hepatitis B evolution that is not evident when using only modern samples.

    • Barbara Mühlemann
    • , Terry C. Jones
    •  & Eske Willerslev

  • Letter |

    Hepatitis A virus is a picornavirus that causes significant morbidity but remains poorly understood; this paper now provides high-resolution crystal structures of both the mature and the empty hepatitis A virus particle, which show that the three-dimensional structure resembles insect picorna-like viruses.

    • Xiangxi Wang
    • , Jingshan Ren
    •  & Elizabeth E. Fry

  • News |

    Success of Chinese biotech partnership raises hopes for prevention of overlooked diseases.

    • Soo Bin Park

  • Outlook |

    The hepatitis C virus is endemic among injection drug users, who could harbour treatment-resistant viruses. We need to adapt to this reality, says Diana Sylvestre

    • Diana Sylvestre

  • Outlook |

    Can doctors calculate a patient's chance of being cured by searching their DNA? Hepatitis C researchers are starting to make this a reality.

    • Amy Maxmen

  • Outlook |

    Egypt has the highest prevalence of hepatitis C worldwide. And the epidemic will soon peak. Prevention demands political will, ample funding and a change in mindset.

    • Mohammed Yahia

  • Outlook |

    With two recently approved drugs and dozens more in the pipeline, hepatitis C treatment will improve over the next decade.

    • Jana Schlütter

  • Outlook |

    The hepatitis C virus has a set of cunning ways to evade immunity, but researchers are turning the immune system on it.

    • Michael Eisenstein

  • Outlook |

    Results ready in minutes and more efficacious drugs will help find and treat the hundreds of millions of carriers.

    • Sarah DeWeerdt

  • News & Views |

    Infection with hepatitis C is one of the main causes of liver disease, yet there are no broadly effective treatments. Discovery of a potent inhibitor of this virus shows that researchers must think outside the box.

    • Catherine L. Murray
    •  & Charles M. Rice

  • Letter |

    Almost 200 million people worldwide are chronically infected with hepatitis C virus. Current treatments are poorly tolerated and not wholly effective, so new drugs are needed. Here, a potent new inhibitor of hepatitis C virus is described. This inhibitor targets the viral protein NS5A, and shows potential as part of a therapeutic regimen based on a combination of viral inhibitors.

    • Min Gao
    • , Richard E. Nettles
    •  & Lawrence G. Hamann

  • Letter |

    Worldwide, 170 million people are infected with the hepatitis C virus, which is a significant cause of liver-related illnesses and deaths. Standard treatment combines pegylated interferon alpha and ribavirin (RBV), but has some negative effects, notably RBV-induced haemolytic anaemia. Here, a genome-wide study shows that a deficiency in the enzyme inosine triphosphatase protects against haemolytic anaemia in patients receiving RBV.

    • Jacques Fellay
    • , Alexander J. Thompson
    •  & David B. Goldstein

Browse broader subjects

Browse narrower subjects

Browse Hepatitis across other nature.com journals